7th TPD and Induced Proximity Summit

With a flurry of high capital collaborations and partnership deals from the likes of C4T, Merck US and KgGA, Monte Rosa, Proxygen, Orum, and momentum building in clinic with BTK degraders, ER degraders and many more assets, it has never been more import to re-join forces at the 7th TPD and Induced Proximity Summit, the longest standing and most comprehensive protein degradation and proximity based conference, returning to Downtown Boston, October 28 - 31, 2024.

Spanning foundational research and discovery, through to IND-filing and clinical trials, this is the world's definitive meeting to discuss opportunities and challenges the TPD and Induced Proximity field must address to expand the target space and facilitate the discovery and development of therapeutically relevant degraders, blockers, stabilizers and inducers of protein-protein interactions. Whether you're entering the TPD and Induced Proximity space for the first time or a well-seasoned TPD veteran, this forum will equip you with the knowhow and connections to make rapid advances in your work.

Assembling over 550 TPD and Induced Proximity enthusiasts from across every corner of the landscape, we have left no stone unturned in our duty to continue to deliver the full breadth and depth of protein degradation and modulation research with SureTACs, EpiTACs, RIPTACs, Molecular Gates, and so much more.

The 7th TPD and Induced Proximity Summit is the field's singular, one-stop-shop to gain unparalleled overview of cutting-edge R and D, whilst diving deep into end-to-end development strategy to propel degraders towards the first clinical approval.

URL:
Tickets: https://go.evvnt.com/2481570-2?pid=154

Prices:
Drug Developer Pricing - (4 Day Pass) Industry Days + New Frontiers Day + Next Generation Day: USD 6295.00,
Drug Developer Pricing - (3 Day Pass) Industry Days + New Frontiers Day OR Next Generation Day: USD 4797.00,
Drug Developer Pricing - (2 Day Pass) Industry Days Only: USD 3299.00,
Academic Pricing - (4 Day Pass) Industry Days + New Frontiers Day + Next Generation Day: USD 5495.00,
Academic Pricing - (3 Day Pass) Industry Days + New Frontiers Day OR Next Generation Day: USD 4197.00,
Academic Pricing - (2 Day Pass) Industry Days Only: USD 2899.00,
Service Provider Pricing - (4 Day Pass) Industry Days + New Frontiers Day + Next Generation Day: USD 7295.00,
Service Provider Pricing - (3 Day Pass) Industry Days + New Frontiers Day OR Next Generation Day: USD 5597.00,
Service Provider Pricing - (2 Day Pass) Industry Days Only: USD 3899.00

Speakers: Abhishek Dogra, Director, Medicinal Chemistry and Induced Proximity, A-Alpha Bio, Adrian Gottschalk, President and Chief Executive Officer, Foghorn Therapeutics, Alessio Ciulli, Director of the Centre for Targeted Protein Degradation, University of Dundee, Amine Sadok, Director, Induced Proximity Platform, Amgen, Andreas Reichel, Vice President, Head Of DMPK Modelling and Simulations, Bayer, Andrew Tsourkas, Professor, University of Pennsylvania, Anita C. Bellail, Chief Scientific Officer and Co-Founder, HB Therapeutics, Ankit Sharma, Associate Director, Medicinal Chemistry, Oncology Targeted Discovery, AstraZeneca, Arnout Schepers, Founder and Chief Executive Officer, TenAces Biosciences, Arthur Sands, President and Chief Executive Officer, Nurix Therapeutics, Arvind Shakya, Director, BioTheryx, Barbara Lueckel, Global Head, Research Technologies Partnering, Pharma Partnering, F. Hoffmann-La Roche, Benedict Cross, CTO, Phoremost, Bernd Boidol, Chief Executive Officer, Proxygen, Bradlee Heckmann, Chief Scientific Officer, Asha Therapeutics, Carolyn Porter, Chief Executive Officer, Outrun Therapeutics, Charu Chaudhry, Senior Principal Scientist, Novartis, Chinatsu Sakata-Sakur, Vice President, Astellas Pharma, Christian Dillon, Chief Scientific Officer, PhoreMost, Christian Ottmann, Associate Professor, Eindhoven University of Technology, Christina Woo, Associate Professor, Harvard University, Dan Finley, Professor, Harvard Medical School, Diogo Feleciano, Co-Founder and Chief Operating Officer, Booster Therapeutics, Dmitri Ivanov, Associate Professor, UT Health San Antonio, Effie Tozzo, Chief Scientific Officer, Avilar Therapeutics, Elena De Vita, Assistant Professor, Queen Mary University of London, Elizabeth Caine, Scientist, Promega, Eric Fischer, Professor and Director Chemical Biology Program Harvard Medical School - Director - DFCI, Center for Protein Degradation, Eugene Chekler, Director, Bristol Myers Squibb, Gang Yao, Associate Director Encoded Oncology, GSK and More

Category: Conferences | Science, Health and Medicine

Date and Time: 28th October 2024 at 9:00 am to 31st October 2024 at 5:00 pm